Cassava Sciences Inc.

277 articles about Cassava Sciences Inc.

• Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

  5/24/2021

  - Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time - - Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group -

• Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -

  5/12/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been awarded a new $2.7 million research grant award from the National Institutes of Health (NIH).

• Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease

  5/10/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of a Cognition Maintenance Study (CMS) to evaluate simufilam in patients with Alzheimer’s disease. Simufilam is a drug candidate that seeks to reduce neurodegeneration and neuroinflammation.

• Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience ConferenceFireside Chat on Wednesday, April 28th at 2:30PM Eastern

  4/27/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 28-29, 2021.

• Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

  4/26/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the Sachs 4 th Annual Neuroscience Innovation Forum, a virtual event held on April 28-30, 2021. T

• Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release

  4/21/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2021 and guidance regarding the release of new clinical data with simufilam.

• Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights

  3/23/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2020 and provided business updates. Unaudited cash and cash equivalents were approximately $280 million as of February 2021.

• Cassava Sciences Announces Pharmaceutical Supply Agreement for Simufilam

  3/9/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced it has entered into a drug supply agreement with Evonik Industries AG for simufilam. Under the agreement, Evonik will supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam,

• Cassava Sciences to Present at the H.C. Wainwright Global Life Sciences Conference

  3/8/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the H.C. Wainwright Global Life Sciences Conference, a virtual event being held Tuesday, March 9th, and Wednesday, March 10th, 2021.

• Cassava Sciences to Present at SVB Leerink Global Healthcare Conference

  2/23/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, has been invited to present at the 10th Annual SVB Leerink Global Healthcare Conference.

• Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease

  2/22/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company developing product candidates for Alzheimer’s disease, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for simufilam, its lead drug candidate for the treatment of Alzheimer’s disease.

• Cassava Sciences Announces Closing of $200 Million Registered Direct Offering

  2/12/2021

  GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million.

• Cassava Sciences Announces $200 Million Registered Direct Offering of Common Stock

  2/10/2021

  Cassava Sciences, Inc. announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 4,081,633 shares of its common stock, at a purchase price per share of $49.00, for gross proceeds of approximately $200.0 million, in a registered direct offering.

• Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease

  2/8/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company developing product candidates for Alzheimer’s disease, today announced significant program progress and expected milestones for 2021.

• Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study

  2/2/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA) today announced results of an interim analysis from an open-label study of simufilam, its lead drug candidate for the treatment of Alzheimer’s disease

• Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer

  1/4/2021

  Cassava Sciences, Inc. (Nasdaq: SAVA) a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the appointment of James Kupiec, MD, to the newly created position of Chief Clinical Development Officer. Dr. Kupiec will lead the Phase 3 clinical development strategy for simufilam, Cassava Sciences’ investigational drug for the treatment of dementia in Alzheimer’s disease. Dr. Kupiec will also serve as a member of the e

• USAN Modifies Lead Drug Candidate’s Chemical Name to ‘Simufilam’Future References to Lead Drug Candidate for Alzheimer’s Disease Will Be Simufilam

  11/27/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the World Health Organization (WHO) advised the United States Adopted Names Council (USAN) to modify the chemical name of the Company’s lead drug candidate to ‘simufilam.’ This change was advised by WHO to avoid a potential trademark conflict with a drug marketed in the Far East. USAN has accepted WHO’s advice. Future references to Cassava Sciences’ lead drug candidate for Alzheimer’s

• Cassava Sciences Announces Pricing of $75 Million Public Offering of Common Stock

  11/13/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the pricing of its previously announced underwritten public offering

• Cassava Sciences Reports Third Quarter 2020 Financial Results

  11/9/2020

  Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today reported financial results for the third quarter ended September 30, 2020. For the third quarter ended September 30, 2020, net loss was $1.4 million, or $0.06 per share, compared to a net loss of $0.7 million, or $0.04 per share, for the same period in 2019. Net cash used in operations was $4.2 million during the first nine month

• Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease

  11/4/2020

  Alzheimer’s Patients Treated with Sumifilam Show ed a Statistically Significant (p < 0. 001 ) Treatment Benefit on HMGB1,  a Protein t hat Triggers Neuroinflammation and Loss of Neurons Alzheimer’s Patients Treated with Sumifilam Also Showed a Treatment Benefit (p<0.05) on Blood-brain B arrier Integrity Clinical Data set to be Presented November 7 th at CTAD 2020 C onference